🚨 🚨 NEW PUBLICATION 🚨 🚨 "The blood-brain barrier imports diverse neuroprotective proteins through pathways impaired early in Alzheimer’s disease models" from @andcyang in @CellCellPress.
@arcinstitute@UCSF
https://t.co/0ojh2cC1JG
Huge thanks to my super amazing mentor @andcyang, everyone in the Yang Lab, all our co-authors and collaborators, and the @GladstoneInst, @UCSF, @BuckInstitute, @EmoryMedicine, and @hkust teams. A true team effort, and it couldn’t be done without every one of you! 7/7
Excited to share our work from the @andcyang lab, now out in @CellCellPress! 🧵 1/7
We asked what the blood-brain barrier lets in, not just what it blocks. It turns out to import neuroprotective blood proteins, and Alzheimer’s models lose this early. 🔗 https://t.co/8oyg6KDjbV
Takeaway: the BBB is a selective interface that recruits circulating proteins for brain health, not just a wall. Peripheral organs like the liver may directly support the brain, and BBB transport dysfunction may be an early step in Alzheimer’s disease. 6/7
Andrew Yang’s lab at Gladstone is working to harness the blood-brain barrier’s transport biology in various ways to treat neurological disease.
Read more about his work and the Sobrato Prize: https://t.co/9ZeTAOc1IE
A gut microbiome signature that tracks with Parkinson's disease severity also appears in healthy people years before symptoms emerge—could a simple stool test one day flag who's at risk? @ucl@ASAP_Research https://t.co/3rO0T6OLl0
Whether microglia devour synapses or freeze up and do nothing, comes down to signals they receive from astrocytes. @UCL@BrighamWomens https://t.co/oJq2aKlYrB
At AD/PD, scientists showed that without ABCA7, cells swell with lipids, lysosomes lose their mojo, and amyloid clearance falters. https://t.co/fJKJHogNNJ
Breaking the amyloid cascade into six distinct phases highlights three key inflection points most amenable to treatment. #alzheimersdisease@KU_Leuven https://t.co/Uyte9doexO
Neurogenesis falls in AD brain but goes up in superagers, who maintain excellent memory with age. Neurogenic cells in superagers activate a unique epigenetic profile. #alzheimersdisease@UofIllinois https://t.co/oOJcvGAg3q
Could CAR-T therapy work for Alzheimer’s? In mice, amyloid-targeting T cells clear deposits from the dura and the brain. @WashU https://t.co/7fdgphRaEA
PET tracers specific for activated and homeostatic microglia are in the works. One targets TREM2, the other P2Y12R. #alzheimersdisease@LMU_Muenchen https://t.co/bQnKplcDyE